Johnson & Johnson

11/08/2024 | Press release | Distributed by Public on 11/08/2024 06:02

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma